CARZEC, a potent antihypertensive agent with a dual mechanism of action. It is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure). With Carzec patient live 1.4 years longer on an average.